<DOC>
	<DOCNO>NCT00275665</DOCNO>
	<brief_summary>This study do stem cell transplant recipient see take drug valganciclovir prevent reduce serious cytomegalovirus ( CMV ) infection occur 100 day later transplant .</brief_summary>
	<brief_title>The Study Being Done See Taking Drug Valganciclovir Can Prevent CMV Infection .</brief_title>
	<detailed_description>This study phase III , randomize , double-blind , palacebo-controlled , multicenter study drug valganciclovir . This study see take prophylactic dos valganciclovir start 100 day stem cell transplantation prevent late CMV occur . Participants randomize ( like flip coin ) one two group . Neither participant doctor know group participant . One group receive drug valganciclovir . The group receive pill look like valganciclovir , contain active medicine ( placebo ) . Participants enrol study take drug mouth daily start day 100 post stem cell transplant . Participants also blood sample take along routine blood weekly , day 270 . Participants also require return routine clinic visit . Participants ' acquire active CMV bloodstream infection time study receive ganciclovir vein twice day high dose valganciclovir . Participants instruct stop taking study drug treatment time . After active CMV infection longer detect , treatment stop . Patients start take study drug monitor CMV bloodstream infection 270 day transplant . Participants develop symptom look like CMV disease ( pneumonia , infection intestine , eye infection ) study drug , examination lab test diagnose organism . Participants hospitalize CMV disease reason ask notify study personnel . Participants need record study medicine take daily study drug diary . Questionnaires fill participant throughout study , also call monthly see feel overall . After 270 day , participant complete study drug phrase . They receive follow phone call day 400 , 520 , 640 day transplant see .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Participants undergo allogeneic peripheral blood stem cell , cord blood , marrow transplantation 18 year age old , may eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>